XSNX (XSNX) Stock Price & Analysis
XSNX (XSNX) rose 0.00% to USD 0 as of September 8, 2026 at 11:17 UTC, according to Nexqual real-time market data.
XSNX last closed at USD 0; the session ranged USD 0–0 on volume of 55,100 shares. Market capitalization is $12,330, with a 52-week range of USD 0–0.05 (PNK). Source: Nexqual, September 8, 2026 at 11:17 UTC.
Key Statistics (as of September 8, 2026 at 11:17 UTC)
| Price | USD 0 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 0 |
| Open | USD 0 |
| Day Range | USD 0 – 0 |
| 52-Week Range | USD 0 – 0.05 |
| Volume | 55,100 shares |
| Market Cap | $12,330 |
| Exchange | PNK |
Technical Analysis (XSNX)
Nexqual's technical model rates XSNX "NEUTRAL" based on 2 bullish and 3 bearish signals across 129 daily candles, as of September 8, 2026 at 11:17 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 100 (overbought) |
| vs SMA50 | Above (USD 0) |
| MACD | 0 (negative) |
Analyst Ratings (XSNX)
Wall Street analysts rate XSNX "None", per Nexqual as of September 8, 2026 at 11:17 UTC.
| Consensus Rating | None |
|---|
Earnings (XSNX)
Source: Nexqual, September 8, 2026 at 11:17 UTC.
Financials & Fundamentals (XSNX)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| Current Ratio | 0.01 |
| Total Cash | $794 |
| Total Debt | $2.28M |
| Free Cash Flow | $1.49M |
Source: Nexqual, September 8, 2026 at 11:17 UTC.
Financial Health Score (XSNX)
Nexqual rates XSNX's overall financial health "Weak" across five dimensions, as of September 8, 2026 at 11:17 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Mixed — $794 cash vs $2M debt |
| Cash Flow | Weak — Operating cash flow -$215K |
| Efficiency | Mixed — No data |
Ownership (XSNX)
| Insider Ownership | +41.12% |
|---|---|
| Institutional Ownership | +8.83% |
| Shares Outstanding | 61.65M |
| Float | 36.30M |
Source: Nexqual, September 8, 2026 at 11:17 UTC.
Leadership (XSNX)
XSNX is led by Dwain K. Morris-Irvin M.P.H. (age 57), CEO, Interim Principal Financial Officer & Director, per Nexqual as of September 8, 2026 at 11:17 UTC.
| CEO, Interim Principal Financial Officer & Director | Dwain K. Morris-Irvin M.P.H. (age 57) |
|---|---|
| President of Stemvax Therapeutics | Christopher Wheeler |
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| SOEN | SOLAR ENERTECH CORP | USD 0 | ▲ 0% |
| SPIR | Spire Global, Inc. | USD 11.98 | ▲ 0.59% |
| BCON | Beacon Holding Company, Inc. | USD 12.5 | ▲ 0% |
| RGUS | REGI U.S., Inc. | USD 0 | ▲ 0% |
| XDSL | mPhase Technologies, Inc. | USD 0 | ▲ 0% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 11:17 UTC. This page is informational and not investment advice.